Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where is the Waste in Part D?

This article was originally published in RPM Report

Executive Summary

Rooting out waste in federal health care spending is one of few points of perennial bipartisan agreement in health policy. In that spirit, a Senate Committee wants to focus on trimming the waste in the Medicare pPrescription drug program-but first they have to figure out where it is.

You may also be interested in...



Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks

Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.

Medicare/Medicaid Prosecutions: Does More Money for Fraud Activities Translate Into More Mega-Settlements?

From expanding health care coverage to collecting fees from miscreants, the lead story at HHS took a quick and sharp turn with the unveiling of the President's budget for fiscal 2011. HHS is setting high return standards for its fraud activities: $1.5 in net returns to the government for every dollar spent. Practically, that may drive HHS to press big pharma for big settlements.

The Opioid REMS: Health Care Reform, One Class at a Time

FDA is planning a spring meeting to discuss next steps in a class-wide Risk Evaluation & Mitigation Strategy for opioids. The outcome will redefine the rules of commercial success in the pain class-and provide a critical case study for how FDA's new regulatory tools may reshape other sectors over time. The good news: there appear to be new opportunities amid the change. The bad: industry is definitely not driving the process.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel